autor: wlobo135 » 15 lis 2014, 11:56
Poniżej wiadomości skopiowane z anglojęzycznego forum dotyczące "flare" po Cabazitaxelu i Abiretronie.
For up to 30% of men, the chemotherapy drug Jevtana (Cabazitaxel) makes the PSA go up for a month or two before it goes down. This rise before a fall is called 'flare'.
This study finds that flare did not make a difference. Even if a man had flare, if Cabazitaxel dropped a man's PSA to half what it was, median survival was around 2 years. (Translation: at around 2 years exactly half the men were still alive.)
Cabazitaxel is mostly used after most other drugs have been tried. It is generally the last chemotherapy drug used to extend life.
Another chemotherapy drug, Mitoxantrone (sometimes spelt mitozantrone), is sometimes used to alleviate symptoms, but Mitoxantrone does not extend life.
An earlier article told us that even if Jetvana (Cabazitaxel) caused the PSA to rise at first (flare), if it then dropped a lot the flare did not make a difference. The same is true for flare in Zytiga (abiraterone).
Micro-Abstract
In a retrospective study, we analyzed the PSA flare after abiraterone treatment in patients with castration-resistant prostate cancer (CRPC) and correlated it with prostate-specific antigen (PSA) declines and clinical outcome. Early PSA flare occurred in 9 of 103 (8.7%) cases. There were no substantial differences in the clinical outcomes between patients who experienced the PSA flare and those who had an immediate PSA response.
Motto: Zanim potępisz staraj się zrozumieć.Ur. 1941
VI/09 PSA5,3 X/09 PSA9,7 Biopsja Gl 9(5+4) Scany: wszystko czyste 30/XI/09 prostatektomia radykalna z usunieciem wiązki nerwowo-naczyniowej.
Gleason 10 pT3aN0M0 21/I/10 PSA 0,7 4/III/10 PSA 0,77. 26/III/10 PSA 1.0 Doubling time 4,5 mca. V/10 hormony (Zoladex) i radioterapia 66Gy.
VIII/10 PSA 0,04 X/10 PSA 0.03 XII/10 PSA 0,03 testosteron 23ng/dL(0,8nml/L)
II/11 PSA<0,05/<0,03 IV/11 PSA<0,05 testosteron<0,5nmol/L(<14ng/dL) Przerwa w hormonoterapii :)
VII/11 PSA 0,001 Testosteron 1,03/30 IX/11
PSA<0.05, Testosteron3.8/112, 11/2011
PSA 0,04 testosteron 7,1/208 1/2012
PSA 0,1 2/2012
PSA 0,18powrót do HT
4/2012 PSA 0,03. 5/2012 PSA<0.03 7/2012 PSA 0,03 9/2012
PSA 0,01 11/2012
PSA <0,03 1/2013
PSA <0,03 3/2013
PSA <0,03 testosteron <23/0,8 Ponowne przerwanie HT 6/2013
PSA <0,003 testosteron<2,6 ng/dl 10/2013
PSA <0,03 testosteron 17,6 ng/dl. 2/2014
PSA<0.03 testosteron 138 7/2014
PSA-0,62, 8/2014
PSA-1,85 10/2014
PSA-7,9 11/2014
PSA-7,57PET/CT zajęte cztery węzły chłonne w miednicy, skierowanie na RT (SBRT) powrót do HT(3 miesiące) 2/2015
PSA-3,43 4/2015
PSA-0,72 7/2015
PSA-0,72 testosteron 40/1,3 10/2015
PSA-1,2 testosteron 168/5,8 12/2015
PSA-0,78 3/2016
PSA-0,71 6/2016
PSA-0,34 9/2016
PSA-0,16 12/2016
PSA-0,22 3/2017
PSA-0,54 7/2017
PSA-1,7 11/2017
PSA-0,3 2/2018
PSA-0,11 5/2018
PSA-0,09 7/2018
PSA-0,169 testosteron 37/1,34 12/2018
PSA-0,22 3/2019
PSA-0,26 6/2019
PSA-0,55 SBRT na jeden "świecący" węzeł chłonny.8/2019
PSA-0,25 11/2019
PSA-0,09 02/2020
PSA-0,06 05/2020
PSA-0,04 08/2020
PSA-0,08 03/2021
PSA-0,88 06/2021
PSA-1,1 09/2021
PSA-1,2 11/2021-SBTR na przykrzyżowe węzły chłonne, 02/2022
PSA-0,06, 06/2022
PSA-0,04,